NEW YORK, Sept. 01, 2017 -- Stull, Stull & Brody (“SS&B”) reminds investors that a class action lawsuit was commenced in the United States District Court for the Eastern District of Missouri on behalf of purchasers of stock of Mallinckrodt Public Limited Company’s (“Mallinckrodt”) (NYSE:MNK), between November 25, 2014 and January 18, 2017 (“Class Period”), in Mallinckrodt’s voluntary and contributory employee benefit plans. If you contributed money in any of Mallinckrodt’s voluntary employee benefit plans and acquired Mallinckrodt ADSs as a result of such contributions, your rights may be affected.
The complaint alleges, among other claims, that Mallinckrodt’s Registration Statement filed with the Securities and Exchange Commission violated Section 11 of the Securities Act of 1933 by omitting material facts and otherwise containing inaccurate, misleading and untrue statements of fact pertaining to, among other things, the long-term sustainability of Mallinckrodt’s revenues for HP Acthar Gel (“Acthar”), the only FDA-approved adrenocorticotropic hormone preparation. The action alleges that Acthar’s monopoly status was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers.
If you purchased or acquired Mallinckrodt stock in any of the Company’s employee benefit plans during the Class Period and wish to serve as a lead plaintiff you may move the Court no later than September 22, 2017; however you must meet certain legal requirements. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Michael Klein, Esq. of SS&B at [email protected], telephone 212-687-7230 x147, or by fax to 212-490-2022.
SS&B has litigated class actions for violations of securities laws and breaches of fiduciary duty on behalf of defrauded investors over the past 40 years and has obtained court approval of substantial settlements on numerous occasions. SS&B has offices in New York and Beverly Hills. SS&B’s website (www.ssbny.com) has additional information about the firm.
Attorney advertising. Prior results do not guarantee a similar outcome. This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules.


KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Apple Turns 50: From Garage Startup to AI Crossroads
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 



